SV, MFSAF, and MPN-SAF response rates at 12 and 24 weeks, in patients treated with add-on parsaclisib plus ruxolitinib
| Response category . | Daily-to-weekly dosing (n = 32) . | All-daily dosing (n = 42) . | Total (N = 74) . |
|---|---|---|---|
| SV | |||
| Week 12, n | 32 | 42 | 74 |
| Response category, n (%) | |||
| <0% reduction | 13 (41) | 6 (14) | 19 (26) |
| 0 to <10% reduction | 6 (19) | 6 (14) | 12 (16) |
| ≥10 to <25% reduction | 8 (25) | 16 (38) | 24 (32) |
| ≥25 to <35% reduction | 1 (3) | 7 (17) | 8 (11) |
| ≥35% reduction | 0 | 2 (5) | 2 (3) |
| Week 24, n | 32 | 42 | 74 |
| Response category, n (%) | |||
| <0% reduction | 8 (25) | 1 (2) | 9 (12) |
| 0 to <10% reduction | 8 (25) | 7 (17) | 15 (20) |
| ≥10 to <25% reduction | 0 | 9 (21) | 9 (12) |
| ≥25 to <35% reduction | 3 (9) | 9 (21) | 12 (16) |
| ≥35% reduction | 1 (3) | 3 (7) | 4 (5) |
| MFSAF | |||
| Week 12, n | 28 | 32 | 60 |
| Response category, n (%) | |||
| <0% reduction | 9 (32) | 4 (13) | 13 (22) |
| 0 to <25% reduction | 5 (18) | 7 (22) | 12 (20) |
| ≥25 to <50% reduction | 3 (11) | 4 (13) | 7 (12) |
| ≥50% reduction | 4 (14) | 9 (28) | 13 (22) |
| Week 24, n | 28 | 32 | 60 |
| Response category, n (%) | |||
| <0% reduction | 7 (25) | 4 (13) | 11 (18) |
| 0 to <25% reduction | 3 (11) | 3 (9) | 6 (10) |
| ≥25 to <50% reduction | 3 (11) | 6 (19) | 9 (15) |
| ≥50% reduction | 3 (11) | 5 (16) | 8 (13) |
| MPN-SAF | |||
| Week 12, n | 27 | 37 | 64 |
| Response category, n (%) | |||
| <0% reduction | 5 (19) | 4 (11) | 9 (14) |
| 0 to <25% reduction | 6 (22) | 4 (11) | 10 (16) |
| ≥25 to <50% reduction | 4 (15) | 10 (27) | 14 (22) |
| ≥50% reduction | 5 (19) | 12 (32) | 17 (27) |
| Week 24, n | 27 | 37 | 64 |
| Response category, n (%) | |||
| <0% reduction | 2 (7) | 2 (5) | 4 (6) |
| 0 to <25% reduction | 2 (7) | 4 (11) | 6 (9) |
| ≥25 to <50% reduction | 6 (22) | 2 (5) | 8 (13) |
| ≥50% reduction | 5 (19) | 18 (49) | 23 (36) |
| Response category . | Daily-to-weekly dosing (n = 32) . | All-daily dosing (n = 42) . | Total (N = 74) . |
|---|---|---|---|
| SV | |||
| Week 12, n | 32 | 42 | 74 |
| Response category, n (%) | |||
| <0% reduction | 13 (41) | 6 (14) | 19 (26) |
| 0 to <10% reduction | 6 (19) | 6 (14) | 12 (16) |
| ≥10 to <25% reduction | 8 (25) | 16 (38) | 24 (32) |
| ≥25 to <35% reduction | 1 (3) | 7 (17) | 8 (11) |
| ≥35% reduction | 0 | 2 (5) | 2 (3) |
| Week 24, n | 32 | 42 | 74 |
| Response category, n (%) | |||
| <0% reduction | 8 (25) | 1 (2) | 9 (12) |
| 0 to <10% reduction | 8 (25) | 7 (17) | 15 (20) |
| ≥10 to <25% reduction | 0 | 9 (21) | 9 (12) |
| ≥25 to <35% reduction | 3 (9) | 9 (21) | 12 (16) |
| ≥35% reduction | 1 (3) | 3 (7) | 4 (5) |
| MFSAF | |||
| Week 12, n | 28 | 32 | 60 |
| Response category, n (%) | |||
| <0% reduction | 9 (32) | 4 (13) | 13 (22) |
| 0 to <25% reduction | 5 (18) | 7 (22) | 12 (20) |
| ≥25 to <50% reduction | 3 (11) | 4 (13) | 7 (12) |
| ≥50% reduction | 4 (14) | 9 (28) | 13 (22) |
| Week 24, n | 28 | 32 | 60 |
| Response category, n (%) | |||
| <0% reduction | 7 (25) | 4 (13) | 11 (18) |
| 0 to <25% reduction | 3 (11) | 3 (9) | 6 (10) |
| ≥25 to <50% reduction | 3 (11) | 6 (19) | 9 (15) |
| ≥50% reduction | 3 (11) | 5 (16) | 8 (13) |
| MPN-SAF | |||
| Week 12, n | 27 | 37 | 64 |
| Response category, n (%) | |||
| <0% reduction | 5 (19) | 4 (11) | 9 (14) |
| 0 to <25% reduction | 6 (22) | 4 (11) | 10 (16) |
| ≥25 to <50% reduction | 4 (15) | 10 (27) | 14 (22) |
| ≥50% reduction | 5 (19) | 12 (32) | 17 (27) |
| Week 24, n | 27 | 37 | 64 |
| Response category, n (%) | |||
| <0% reduction | 2 (7) | 2 (5) | 4 (6) |
| 0 to <25% reduction | 2 (7) | 4 (11) | 6 (9) |
| ≥25 to <50% reduction | 6 (22) | 2 (5) | 8 (13) |
| ≥50% reduction | 5 (19) | 18 (49) | 23 (36) |
Evaluable patients were those receiving ≥1 dose of study drug, had SV, MFSAF, or MPN-SAF baseline assessment with a nonzero value, and met ≥1 of the following criteria: (1) had week 12 or 24 SV, MFSAF, or MPN-SAF assessments; and (2) had been on the study for a minimum of 89 or 173 days of follow-up; or (3) had discontinued from treatment on, or before, week 12 or 24. Noncompleters were assessed as nonresponders.